Clinical Trials · NCT06604624
Semaglutide in Treatment of Obesity
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Enrollment
- 462
- Start date
- Sep 2024
- Locations
- 1 site, China
- Primary endpoint
- Relative percentage change in body weight from baseline at 44 weeks of treatment